RÉSUMÉ
Background: Multidrug-resistant Enterococci are major problem and are increasingly reported worldwide. Enterococcal infections have been associated with higher hospitalization costs and a higher number of related deaths. Treatment of multidrug-resistant enterococci has become a challenge in hospitals around the world due to the lack of reliable therapeutic options. So the present study was undertaken with the aim to know the antimicrobial resistantpattern of enterococcus to newer antibiotic. Methodology: 22 isolates of enterococcus resistant to the entire routinely tested antibiotic were further tested for newer antimicrobial agent linezolid, daptomycin, rifampin, synercid, teicoplanin, telavancin, vancomycin, gentamicin (HLG). Results: Among these 22 enterococci isolated none of our isolates showed resistance to vancomycin, teicoplanin, telavancin, tigecycline and linezolid. But one isolate of E.faecalis showed resistance to daptomcyin. This daptomycinnonsusceptible isolate was found susceptible to ceftaroline. E. faecalis showed higher resistance to Gentamicin (HLG) and Synercid as compared to E.faecium. Specimen-wise higher distribution of enterococci (resistant to routinely tested antimicrobial agents) was observed in Urine 11(50%) followed by Pus 4(18.18%) and Miscellaneous 4(18.18%) and from Blood 3(13.64%). Conclusion: In our study none of the isolates showed resistance to vancomycin, tigecycline, telavancin, linezolid and ceftaroline but thepresence of daptomycin non-susceptible enterococci 1(4.55%) in our rural set-up is cause of concern.